162 related articles for article (PubMed ID: 38028569)
1. Entrectinib for NTRK Fusion-Positive Metastatic Melanoma Progressing on Combined PD-1 and CTLA-4 Inhibition: A Case Report.
Dawood S; Ali ZJ
Case Rep Oncol; 2023; 16(1):1451-1459. PubMed ID: 38028569
[TBL] [Abstract][Full Text] [Related]
2. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
[TBL] [Abstract][Full Text] [Related]
3. Case Report: A case of complete response to entrectinib in
Moriyama E; Nagasu S; Tanaka T; Shimotsuura Y; Ono T; Umeno H; Akiba J; Kawahara A; Fujita F; Kawaguchi T; Miwa K
Front Oncol; 2023; 13():1247435. PubMed ID: 37601665
[TBL] [Abstract][Full Text] [Related]
4. Case report:
Lazzari C; Pecciarini L; Doglioni C; Pedica F; Gajate AMS; Bulotta A; Gregorc V; Cangi MG
Front Oncol; 2022; 12():1038774. PubMed ID: 36419889
[TBL] [Abstract][Full Text] [Related]
5. Activity of Entrectinib in a Patient With the First Reported
Sigal D; Tartar M; Xavier M; Bao F; Foley P; Luo D; Christiansen J; Hornby Z; Maneval EC; Multani P
J Natl Compr Canc Netw; 2017 Nov; 15(11):1317-1322. PubMed ID: 29118225
[TBL] [Abstract][Full Text] [Related]
6. TRK Inhibition with Entrectinib in Metastatic Salivary Secretory Carcinoma (SC): A Case Report.
Ernst MS; Lysack JT; Hyrcza MD; Chandarana SP; Hao D
Curr Oncol; 2022 May; 29(6):3933-3939. PubMed ID: 35735423
[TBL] [Abstract][Full Text] [Related]
7. Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib.
Wu WC; Chen MH
Front Oncol; 2022; 12():1031396. PubMed ID: 36703785
[TBL] [Abstract][Full Text] [Related]
8. TRK inhibitor in a patient with metastatic triple-negative breast cancer and
Medford AJ; Oshry L; Boyraz B; Kiedrowski L; Menshikova S; Butusova A; Dai CS; Gogakos T; Keenan JC; Occhiogrosso RH; Ryan P; Lennerz JK; Spring LM; Moy B; Ellisen LW; Bardia A
Ther Adv Med Oncol; 2023; 15():17588359231152844. PubMed ID: 36743521
[TBL] [Abstract][Full Text] [Related]
9. Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion.
Mortensen L; Ordulu Z; Dagogo-Jack I; Bossuyt V; Winters L; Taghian A; Smith BL; Ellisen LW; Kiedrowski LA; Lennerz JK; Bardia A; Spring LM
Oncologist; 2021 Oct; 26(10):818-824. PubMed ID: 34176200
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated
Mayr L; Guntner AS; Madlener S; Schmook MT; Peyrl A; Azizi AA; Dieckmann K; Reisinger D; Stepien NM; Schramm K; Laemmerer A; Jones DTW; Ecker J; Sahm F; Milde T; Pajtler KW; Blattner-Johnson M; Strbac M; Dorfer C; Czech T; Kirchhofer D; Gabler L; Berger W; Haberler C; Müllauer L; Buchberger W; Slavc I; Lötsch-Gojo D; Gojo J
J Pers Med; 2020 Dec; 10(4):. PubMed ID: 33353026
[TBL] [Abstract][Full Text] [Related]
11. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
12. Entrectinib use in a platinum-refractory mucinous ovarian cancer harboring a NTRK3 gene fusion.
Beck OG; Hardesty MM
Gynecol Oncol Rep; 2023 Jun; 47():101187. PubMed ID: 37122438
[TBL] [Abstract][Full Text] [Related]
13. Isolated Leptomeningeal Progression in a Patient with NTRK Fusion+ Uterine Sarcoma: A Case Report.
Lanman T; Hayden Gephart M; Bui N; Toland A; Nagpal S
Case Rep Oncol; 2021; 14(3):1841-1846. PubMed ID: 35111018
[TBL] [Abstract][Full Text] [Related]
14. Real-world experience of tropomyosin receptor kinase inhibition with entrectinib in ETV6-NTRK3 positive metastatic salivary secretory carcinoma: A case series.
Yokota T; Yukino H; Doi M; Ohori H
Head Neck; 2023 May; 45(5):E10-E15. PubMed ID: 36924196
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
[TBL] [Abstract][Full Text] [Related]
16. Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report.
Damásio I; Simões-Pereira J; Donato S; Horta M; Cavaco BM; Rito M; Gomes P; Leite V
Eur Thyroid J; 2023 Feb; 12(1):. PubMed ID: 36378538
[TBL] [Abstract][Full Text] [Related]
17. NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer.
Koehler VF; Achterfeld J; Sandner N; Koch C; Wiegmann JP; Ivanyi P; Käsmann L; Pusch R; Wolf D; Chirica M; Knösel T; Demes MC; Kumbrink J; Vogl TJ; Meyer G; Spitzweg C; Bojunga J; Kroiss M
J Cancer Res Clin Oncol; 2023 Nov; 149(15):14035-14043. PubMed ID: 37548775
[TBL] [Abstract][Full Text] [Related]
18. Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors.
Hibar DP; Demetri GD; Peters S; Davies J; Humblet O; Maund SL; Perez L
PLoS One; 2022; 17(8):e0270571. PubMed ID: 35939431
[TBL] [Abstract][Full Text] [Related]
19. Case Report: Identification of a novel
Yu QX; Zhao WJ; Wang HY; Zhang L; Qin L; Zhang L; Han JL
Front Oncol; 2023; 13():1123812. PubMed ID: 37188179
[No Abstract] [Full Text] [Related]
20. Cost-Effectiveness Analysis of Treating Patients With NTRK-Positive Cancer With the Histology-Independent Therapy Entrectinib.
Huygens S; Vellekoop H; Versteegh M; Santi I; Szilberhorn L; Zelei T; Nagy B; Tsiachristas A; Koleva-Kolarova R; Wordsworth S; Rutten-van Mölken M;
Value Health; 2023 Feb; 26(2):193-203. PubMed ID: 36229359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
